In order to meet the domestic urgent needs of evaluating the immunogenicity of vaccines and the potency testing of therapeutic antibody products against coronavirus disease 2019 (COVID-19), the first Chinese national standards for SARS-CoV-2 neutralizing antibody were established. The potency and stability of the candidate standards were determined by neutralization assay and accelerated degradation study. The stability studies showed that the standards were stable in the short-term. The collaborative study showed that the candidate standards could reduce the variations in neutralization titers between labs and thus improve comparability of neutralizing antibody measurements. Sample 22 has been approved by the Biological Product Reference Standards Sub-Committee of the National Drug Reference Standards Committee as the first Chinese National Standard for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) neutralizing antibody, with an assigned potency of 1,000 units per milliliter (U/ml). This standard will contribute to the standardized assessment of the quality and efficacy of vaccines and therapeutics for COVID-19 in China.
【저자키워드】 COVID-19, neutralizing antibody, SARS-CoV-2, Neutralization assay, Standard, 【초록키워드】 coronavirus disease, neutralizing antibody, Coronavirus disease 2019, Efficacy, Vaccine, immunogenicity, antibody, Therapeutics, Variation, severe acute respiratory syndrome coronavirus-2, drug, severe acute respiratory syndrome Coronavirus, China, Severe acute respiratory syndrome, stability, Neutralization assay, therapeutic, variations, Degradation, respiratory, reference standard, SARS-CoV-2 neutralizing antibody, neutralization titers, Reference standards, Biological, comparability, determined by, national standards, Chinese, product, potency, U/mL, National, neutralization titer, milliliter, lab, Biological product, Committee, IMPROVE, Sample, approved, contribute, reduce, assigned, accelerated, 【제목키워드】 Chinese, National,